One hundred million dollars over five years. That's how much the SRI International biosciences division is being awarded as part of a contract to research and develop products to address the effects of radiation exposure.
The multi-year contract was awarded by the National Institute of Allergy and Infectious Disease, part of the National Institutes of Health.
The principal investigator for the contract will be Polly Chang, senior director of molecular and genetic toxicology at SRI Biosciences. The award will support work related to developing medical "countermeasures" to address the effects of radiation and nuclear exposure.
SRI International is based in Menlo Park.